Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

On Ask The Doctor, Dr Vinay Gupta,&nbsp;Dr. Vinay Gupta, Lung/ICU Doctor, Faculty, Institute of Health Metrics and Evaluation, Covid 19 CMO, Amazon Care, says we shouldn't be focussing on drugs like Ivermection &amp; Remdesivir based on just anecdotal data. He adds, Ivermectin Is a dangerous drug and the doses required to kill Covid are very high which if used without medical supervision can cause liver and vital organ injury. Dr Kavita,&nbsp;Fellow, Brookings Institution, General Practitioner in Washington D.C.,&nbsp;says Remdesivir is not a miracle drug and indicriminate use can lead to more harm than good.

Ask The Doctor | Using Remdesivir & Ivermectin safe to use in Covid patients? Doctors explain

On Ask The Doctor, Dr Vinay Gupta,&nbsp;Dr. Vinay Gupta, Lung/ICU Doctor, Faculty, Institute of Health Metrics and Evaluation, Covid 19 CMO, Amazon Care, says we shouldn't be focussing on drugs like Ivermection &amp; Remdesivir based on just anecdotal data. He adds, Ivermectin Is a dangerous drug and the doses required to kill Covid are very high which if used without medical supervision can cause liver and vital organ injury. Dr Kavita,&nbsp;Fellow, Brookings Institution, General Practitioner in Washington D.C.,&nbsp;says Remdesivir is not a miracle drug and indicriminate use can lead to more harm than good.

Plasma therapy could be dropped from clinical management protocol of Covid-19 as ICMR&rsquo;s expert panel found that the therapy wasn&rsquo;t beneficial in reducing the progression to severe disease or death of patients, a CNN-News18 report said quoting sources.
The Indian Council of Medical Research is expected to issue an advisory on the same in the next few days. India&rsquo;s national task force on Covid-19 management met on Friday, to review the convalescent plasma therapy for infected patients. The present guidelines allow &ldquo;off label" use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of Covid-19 symptoms and if there is availability of donor plasma.
A group of 18 clinicians, scientists and public health professionals had recently written to the government, saying the &ldquo;irrational use&rdquo; of plasma therapy &ldquo;raises the possibility of more virulent strains&rdquo; of Sars-Cov-2, the virus that causes Covid-19. In their letter, the experts cited three studies &mdash; the ICMR-PLACID Trial, the Recovery Trial conducted by the University of Oxford, and Argentina&rsquo;s PlasmAr Trial &mdash; to argue that the country&rsquo;s existing guidelines on plasma therapy were not based on evidence.

Plasma therapy to be dropped from ICMR's Covid protocols?

Plasma therapy may be dropped from ICMR's Covid&nbsp;management&nbsp;protocols, say reports; experts argue it may not be effective

Plasma therapy could be dropped from clinical management protocol of Covid-19 as ICMR&rsquo;s expert panel found that the therapy wasn&rsquo;t beneficial in reducing the progression to severe disease or death of patients, a CNN-News18 report said quoting sources.
The Indian Council of Medical Research is expected to issue an advisory on the same in the next few days. India&rsquo;s national task force on Covid-19 management met on Friday, to review the convalescent plasma therapy for infected patients. The present guidelines allow &ldquo;off label" use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of Covid-19 symptoms and if there is availability of donor plasma.
A group of 18 clinicians, scientists and public health professionals had recently written to the government, saying the &ldquo;irrational use&rdquo; of plasma therapy &ldquo;raises the possibility of more virulent strains&rdquo; of Sars-Cov-2, the virus that causes Covid-19. In their letter, the experts cited three studies &mdash; the ICMR-PLACID Trial, the Recovery Trial conducted by the University of Oxford, and Argentina&rsquo;s PlasmAr Trial &mdash; to argue that the country&rsquo;s existing guidelines on plasma therapy were not based on evidence.

plasma therapy

Categories